Glenmark's drug fails in their clinical trials

Switzerland based Glenmark Pharmaceuticals is a subsidiary of Glenmark Pharmaceuticals India (GPL) said that its molecule under development Oglemilast has failed to give up positive results in clinical trials for Chronic Obstructive Pulmonary Disease (COPD), a sharp form of smoking induced lung disease.Glenmark had licensed the potential drug to US-based Forest Laboratories, who was conducting clinical trials to develop the drug for COPD and asthma.
“Oglemilast is an orally administered PDE 4 inhibitor, which we consider to be an important and novel therapeutic target for COPD. We are, of course, disappointed that Oglemilast has not been successful in this study,” said Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories.this molecule is also undergoing trials to check if it can be useful in treating asthma. "The results are expected during the 1st quarter of 2010. We are considering together with Glenmark what further action would be helpful or suitable," said Solomon.